南京高科股份有限公司 | 变更前 | 变更后 | | --- | --- | | 许可项目：房地产开发经营；建设工程 | 许可项目：房地产开发经营；建设工程 | | 施工；建设工程监理。（依法须经批准 | 施工；建设工程监理；药品生产；药品 | | 的项目，经相关部门批准后方可开展经 | 批发。（依法须经批准的项目，经相关 | | 营活动，具体经营项目以相关部门批准 | 部门批准后方可开展经营活动，具体经 | | 文件或许可证件为准）。 | 营项目以相关部门批准文件或许可证 | | 一般项目：股权投资；创业投资（限投 | 件为准）。 | | 资未上市企业）；以自有资金从事投资 | 一般项目：股权投资；创业投资（限投 | | 活动；企业总部管理；非居住房地产租 | 资未上市企业）；以自有资金从事投资 | | 赁；住房租赁；商业综合体管理服务； | 活动；非居住房地产租赁；住房租赁； | | 物业管理；土地整治服务；工程管理服 | 商业综合体管理服务；物业管理；工程 | | 务；市政设施管理；污水处理及其再生 | 管理服务；市政设施管理；污水处理及 | | 利用；水环境污染防治服务。（除依法 | 其再生利用；水环 ...

证券简称：南京高科 证券代码：600064 编号：临 2024-039 号 南京高科股份有限公司 第十一届董事会第四次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 南京高科股份有限公司第十一届董事会第四次会议于 2024 年 11 月 1 日以通讯表决方式召开。会议通知于 2024 年 10 月 28 日以邮件 和电话的方式发出。本次会议应参加表决的董事 7 名，实际参加表决 的董事 7 名，符合《公司法》和《公司章程》的有关规定。本次会议 审议并通过了以下议案： 一、关于变更公司经营范围暨修订《公司章程》相关条款的议案； 二、关于变更公司证券事务代表的议案。 因内部工作岗位调整，公司证券事务代表蒋奇辰先生不再担任该 职务。同意聘任陈沛先生（简历见附件）为公司证券事务代表，任期 与公司第十一届董事会一致。 表决结果：同意 7 票，反对 0 票，弃权 0 票，表决通过。 特此公告。 南京高科股份有限公司 董 事 会 二○二四年十一月五日 1 （详见《南京高科股份有限公司关于变更公司经营范围暨修订< 公司章程 ...

Revenue and Profitability - The company's operating revenue decreased by 67.85% in the third quarter compared to the same period last year, totaling ¥1,514,253,724.27[2] - Net profit attributable to shareholders increased by 59.33% in the third quarter, amounting to ¥1,838,210,180.62[2] - The net profit attributable to shareholders after deducting non-recurring gains and losses rose by 46.32%, reaching ¥1,747,140,768.04[2] - Basic earnings per share for the third quarter were ¥1.062, reflecting a 10.05% increase year-on-year[3] - The company achieved a contract sales amount of 197.95 million RMB, down 89.32% year-on-year, with equity contract sales amounting to 138.88 million RMB, a decrease of 91.39%[11] - Net profit attributable to shareholders for the first three quarters of 2024 was CNY 1,838,210,180.62, an increase of 10.09% from CNY 1,669,878,471.65 in the same period of 2023[18] - Operating profit for the first three quarters of 2024 was CNY 1,897,771,742.21, up from CNY 1,724,010,116.00 in 2023, indicating a growth of about 10.09%[18] - Basic earnings per share for the first three quarters of 2024 were CNY 1.062, compared to CNY 0.965 in the same period of 2023, representing an increase of approximately 10.05%[19] - The total comprehensive income for the first three quarters of 2024 was ¥1,984,288,932.35, an increase of 24.4% from ¥1,594,890,613.29 in the first three quarters of 2023[27] Assets and Liabilities - The total assets at the end of the reporting period were ¥39,390,003,596.05, representing a 5.65% increase from the end of the previous year[3] - The equity attributable to shareholders increased by 8.37% to ¥19,006,802,678.02 compared to the end of the previous year[3] - As of September 30, 2024, the company's total assets reached 39.39 billion RMB, an increase from 37.28 billion RMB at the end of 2023[15] - The company's total liabilities decreased to approximately 18.68 billion RMB from 19.59 billion RMB at the end of 2023[15] - The total assets increased to 25,915,896,244.20 RMB, up from 24,870,850,052.61 RMB at the end of 2023[24] - The company's total liabilities decreased to 8,020,919,394.69 RMB from 9,035,889,988.17 RMB year-over-year[24] Cash Flow - The company reported a cash flow from operating activities of -¥636,913,469.36 for the reporting period[2] - The cash flow from operating activities for the first three quarters of 2024 was CNY 1,264,050,901.49, a decrease from CNY 2,026,147,947.73 in the same period of 2023, indicating a decline of about 37.66%[20] - The net cash flow from operating activities for Q3 2024 was -636,913,469.36 RMB, an improvement from -1,453,231,217.73 RMB in Q3 2023[21] - The cash flow from operating activities showed a net outflow of ¥285,434,003.68 in the first three quarters of 2024, an improvement from a net outflow of ¥823,076,693.89 in the same period of 2023[28] Investment and Financing Activities - Total cash inflow from investment activities was 1,098,363,580.55 RMB, compared to 970,356,725.89 RMB in the same period last year[22] - The net cash flow from financing activities decreased to -271,761,409.71 RMB from 1,187,870,011.83 RMB year-over-year[22] - The company received 8,249,000,000.00 RMB in cash from borrowings, a decrease from 10,223,760,000.00 RMB in Q3 2023[22] - Investment activities generated a net cash inflow of ¥957,152,099.39 in the first three quarters of 2024, compared to ¥593,800,516.85 in the same period of 2023, indicating a significant increase of 61.2%[29] Shareholder Information - The top shareholder, Nanjing New Port Development Co., Ltd., holds 34.74% of the shares, with 601,083,220 shares frozen[7] - The company is actively addressing the judicial freeze of 229 million shares, which represents 38.10% of the shares held by Nanjing New Port Development Co., Ltd.[13] Research and Development - Research and development expenses increased to CNY 19,652,583.87 in the first three quarters of 2024, compared to CNY 8,513,625.14 in the same period of 2023, reflecting a significant increase of approximately 131.06%[18]

证券简称：南京高科 证券代码：600064 编号：临 2024-038 号 南京高科股份有限公司 2024 年第三季度网上业绩说明会预告公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 欢迎投资者于 2024 年 10 月 31 日前将关注的问题通过电子邮件的形式发 送至本公司邮箱：600064@600064.com。公司将通过业绩说明会在信息披露允许 的范围内对投资者普遍关注的问题进行解答。 一、说明会类型 公司已于 2024 年 10 月 24 日在《中国证券报》《上海证券报》《证 券时报》及上海证券交易所网站（www.sse.com.cn）上披露了 2024 年第三季度报告。为让广大投资者更全面深入的了解公司经营业绩等 具体情况，公司决定以网络互动方式举行"2024 年第三季度业绩说 明会"。 二、说明会召开时间和形式 召开时间：2024 年 11 月 1 日（周五）15:00-16:00 召开形式：网络文字互动 公司董事长、党委书记徐益民先生，董事、总裁陆阳俊先生，独 1 会议时间：2024 ...

证券简称：南京高科 证券代码：600064 编号：临 2024-036 号 南京高科股份有限公司 第十一届董事会第三次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 南京高科股份有限公司第十一届董事会第三次会议于 2024 年 10 月 22 日上午 9:30 在公司会议室召开。会议通知于 2024 年 10 月 14 日以邮件和电话的方式发出。本次会议应到董事 7 名，实到 7 名，公 司监事及高级管理人员列席了会议，符合《公司法》和《公司章程》 的有关规定。本次会议审议并通过了以下议案： 一、2024 年第三季度报告； （详见上海证券交易所网站 www.sse.com.cn） 表决结果：同意 7 票，反对 0 票，弃权 0 票，表决通过。 2020 年 7 月，基于行业环境和公司战略规划，为了加强统筹房 地产、市政业务板块产业链重点项目协同拓展工作，经董事会审议通 过，公司总部设立了市场拓展部，负责公司房地产市政业务市场调研 与业务拓展工作。 近年来房地产行业持续深度调整，当前公司已明确利用 3-5 年 ...

证券简称：南京高科 证券代码：600064 编号：临 2024-037 号 南京高科股份有限公司关于延长南京高科新浚成长一期股 权投资合伙企业(有限合伙)存续期的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 一、基本情况概述 南京高科股份有限公司（以下简称"公司"）于 2015 年 9 月 25 日召开的第八届董事会第三十次会议审议通过了《关于投资设立南京 高科新浚投资管理有限公司等企业的公告》（详见公司临 2015-031 号 公告），同意公司投资设立南京高科新浚成长一期股权投资合伙企业 (有限合伙)（以下简称"新浚一期基金"）。新浚一期基金认缴出资总 额为人民币 100,000 万元，其中南京高科新浚股权投资合伙企业(有限 合伙)以现金出资 500 万元，出资比例为 0.5%，担任普通合伙人；公 司、浙江嘉立控股股份有限公司分别以现金出资 69,650 万元、29,850 万元，出资比例分别为 69.65%、29.85%，担任有限合伙人。为提升 基金运作效率，公司董事会同意授权公司董事长处理与该基金有关的 具 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 南京高科股份有限公司（以下简称"公司"）于 2023 年 5 月 25 日召开公司 2022 年年度股东大会，审议通过了《关于公司发行短期 融资券的议案》，同意公司向中国银行间市场交易商协会申请注册发 行不超过人民币 20 亿元（含 20 亿元）的短期融资券。2024 年 1 月 31 日，中国银行间市场交易商协会接受公司短期融资券注册。根据 中市协注[2024]CP26 号《接受注册通知书》，公司短期融资券注册金 额为 19 亿元，注册额度自通知书落款之日（2024 年 2 月 7 日）起 2 年内有效，公司在注册有效期内可分期发行短期融资券。 证券简称：南京高科 证券代码：600064 编号：临 2024-035 号 南京高科股份有限公司 2024 年度第二期短期融资券发行结果公告 本次短期融资券发行的有关文件详见中国货币网（www.chinamo ney.com.cn）和上海清算所网站（www.shclearing.com.cn）。 特此公告。 南京高科股份有限公司 ...

证券简称：南京高科 证券代码：600064 编号：临 2024-034 号 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 根据《上海证券交易所上市公司自律监管指引第 3 号——行业信 息披露》要求，特此公告南京高科股份有限公司（以下简称"公司"） 2024 年第 3 季度房地产业务相关经营数据。 2024 年 1-9 月，公司无新增房地产项目储备。 2024 年 7-9 月，公司房地产业务无新开工，无新竣工。2024 年 1-9 月，公司房地产业务新开工面积 5.16 万平方米，权益新开工面积 3.72 万平方米；竣工面积 6.17 万平方米，权益竣工面积 4.93 万平方 米。 2024 年 7-9 月，公司房地产业务实现合同销售面积 0.18 万平方 米（均为商品房项目销售），同比减少 47.06%，实现权益合同销售面 积 0.12 万平方米（均为商品房项目销售），同比减少 61.29%；实现合 同销售金额 7,488.68 万元（均为商品住宅、车位等项目销售），同比 减少 36.81%，实现权益合同销售金额 5, ...

Investment Rating - The investment rating for the company is "Outperform the Market" and is maintained [1] Core Views - The company reported a significant decline in revenue and net profit for the first half of 2024, with operating income of 1.044 billion yuan, down 62.35% year-on-year, and net profit attributable to the parent company of 1.023 billion yuan, down 11.69% year-on-year [5] - The municipal revenue showed growth, with municipal business revenue reaching 598 million yuan, an increase of 30.23% year-on-year, while the real estate business faced substantial declines in both sales area and revenue [5] - The company is focusing on technological innovation and market expansion in sectors such as biomedicine and semiconductor materials, and has become the largest shareholder of Chenpai Pharmaceutical [5][6] - The company has a low debt level, with a debt-to-asset ratio of 49.16% and an average financing cost of 2.81%, which is a decrease of 0.27 percentage points year-on-year [6] - The reasonable value range for the company's stock is estimated to be between 6.00 and 7.00 yuan, with projected EPS for 2024 and 2025 at 1.00 yuan and 1.11 yuan respectively [6] Summary by Sections Financial Performance - In the first half of 2024, the real estate business saw a contract sales area of 0.27 million square meters, a decrease of 98.92%, and a contract sales amount of 123 million yuan, down 92.91% year-on-year [5] - The company achieved an investment income of 1.057 billion yuan, a decrease of 7.32% year-on-year, and a fair value change loss of 112 million yuan [5] Future Outlook - The company plans to continue analyzing market and industry trends to enhance competitiveness and promote stable business development [6] - The company aims to innovate sales strategies and actively explore policies to boost sales and cash flow in the real estate sector [6] Valuation Metrics - The projected financial metrics for the company include operating income of 5.073 billion yuan for 2024, with a year-on-year growth of 7.2%, and net profit of 1.728 billion yuan, reflecting a year-on-year growth of 10.8% [8] - The company’s average financing cost is expected to remain low, supporting its operational efficiency [6]

Investment Rating - The report maintains a "Buy" rating for Nanjing Gaoke (600064 SH) [1][3] Core Views - Revenue and net profit declined in H1 2024, with revenue down 62 35% YoY to 1 044 billion yuan and net profit down 11 69% YoY to 1 023 billion yuan [3] - Gross margin improved by 5 75 percentage points to 16 92%, while net margin surged by 56 55 percentage points to 98 64% due to a significant increase in investment income relative to revenue [3] - The company's diversified business and smooth financing channels are expected to drive continuous performance improvement [3] Business Performance - Real estate development revenue dropped 80 73% YoY to 446 million yuan, while municipal infrastructure construction revenue grew 46 07% YoY to 430 million yuan [4] - Investment income decreased by 7 32% YoY to 1 057 billion yuan, with a fair value change loss of 112 million yuan [4] - The company held securities with a book value of 2 494 billion yuan as of June 30, 2024 [4] Financial Performance - Operating cash flow was negative at 592 million yuan in H1 2024, indicating room for improvement [5] - The company's asset liability ratio stood at 49 16%, with a current ratio of 1 18 and a quick ratio of 0 42 [5] - Period expenses increased by 2 percentage points to 2 98% [5] Financing and Liquidity - The company issued two tranches of ultra short term bonds totaling 1 25 billion yuan in H1 2024, with coupon rates of 2 73% and 2 35%, maintaining low financing costs [6] - As of June 30, 2024, the company had a loan balance of 500 million yuan with Nanjing Bank, with total interest payments of 7 1778 million yuan in H1 2024 [6] Valuation and Forecast - The report forecasts net profit of 1 91 billion yuan, 2 21 billion yuan, and 2 46 billion yuan for 2024 2026, with EPS of 1 1 yuan, 1 3 yuan, and 1 4 yuan respectively [3] - The current stock price implies a PE ratio of 5 2x, 4 5x, and 4 1x for 2024 2026 [3]